Delpharm is one of the world's top five CDMOs, specializing in the development and manufacture of medicines across solid, sterile, semi-solid, and liquid dosage forms with particular expertise in nasal sprays and injectables. The company operates 18 manufacturing sites and 3 development centers across Europe and North America, with 6,500 employees and over 1.1 billion EUR in turnover. Delpharm produces over 650 million units annually and recently received a $60 million Canadian government investment to modernize its Boucherville injectable facility.
Nasal spray manufacturing, sterile fill/finish, prefilled syringes, solid dose, semi-solid forms, blow-fill-seal, high potent drugs
5 sites worldwide
No reviews available yet.
No documents available.